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ABSTRACT Rational characterization of virulence and host-adaptive markers in the
multifunctional inﬂuenza A virus NS1 protein is hindered by a lack of comprehensive
knowledge about NS1-host protein protein interfaces. Here, we surveyed the impact
of amino acid variation in NS1 at its structurally deﬁned binding site for host p85,
a regulator of phosphoinositide 3-kinase (PI3K) signaling. Structure-guided alanine
scanning of all viral residues at this interface deﬁned 10 positions contributing to
the interaction, with residues 89, 95, 98, 133, 145, and 162 being the most impor-
tant. A bioinformatic study of 24,000 publicly available NS1 sequences derived
from viruses infecting different hosts highlighted several prevalent amino acid vari-
ants at the p85 interface that either enhanced (I95) or weakened (N135, T145,
L161, Y161, S164) p85 binding. Interestingly, analysis of viruses circulating in hu-
mans since the 1918 pandemic revealed the temporal acquisition of functionally rel-
evant variants at this interface. I95 (which enhanced p85 binding) quickly became
prevalent in the 1940s and experimentally conferred a ﬁtness advantage to a recom-
binant 1930s-based H1N1 virus in human lung epithelial cells. Surprisingly, H1N1
and H3N2 viruses recently acquired T145 or N135, respectively, which diminished
p85 binding but apparently not the overall ﬁtness in the human population. Evolu-
tionary analyses revealed covariation of the NS1-p85 binding phenotype in humans
with functional changes at multiple residues in other viral proteins, suggesting an
unexplored compensatory or synergistic interplay between phenotypes in vivo. Over-
all, our data provide a resource to understand the consequences of the NS1-p85
binding spectrum of different inﬂuenza viruses and highlight the dynamic evolution
of this property in viruses circulating in humans.
IMPORTANCE In humans, inﬂuenza A viruses are responsible for causing seasonal
epidemics and occasional pandemics. These viruses also circulate and evolve in
other animal species, creating a reservoir from which novel viruses with distinct
properties can emerge. The viral nonstructural protein NS1 is an important host
range determinant and virulence factor that exhibits strain-speciﬁc interactions with
several host factors, although few have been characterized extensively. In the study
described here, we comprehensively surveyed the impact of natural and unnatural
NS1 variations on the binding of NS1 to host p85, a subunit of phosphoinositide
3-kinase that regulates intracellular metabolism and contributes to virus replication
and virulence. We deﬁne the p85-binding site on NS1 and provide a predictive re-
source to assess this ability of NS1 in viruses from different hosts. Strikingly, we un-
cover a spectrum of p85 binding by different NS1 proteins and reveal that viruses
evolving in humans have undergone dynamic changes in this NS1 function over the
last century.
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The inﬂuenza A virus (IAV) NS1 protein plays a critical role in reprogramming host cellsignaling pathways during infection to promote efﬁcient viral replication (reviewed
in references 1 to 3). A major function of NS1 is to directly antagonize host interferon
(IFN) responses by preventing the full activation of RIG-I, either by sequestering away
its double-stranded RNA trigger or by interfering with regulatory posttranslational
modiﬁcations mediated by the E3 ubiquitin ligases TRIM25 and Riplet (4–7). In addition,
some NS1 proteins can indirectly prevent IFN synthesis by inhibiting almost all cellular
gene expression in infected cells, a property related to binding the host pre-mRNA
processing machinery component CPSF30 (8, 9). NS1 proteins have also been reported
to engage with several other factors to manipulate the host environment, including the
p85 regulatory subunit of phosphoinositide 3-kinase (PI3K) (10–13), PAF1 (14), DDX21
(15), PACT (16), protein kinase R (17), Crk/CrkL (18, 19), and several PDZ-domain
containing proteins (20–23).
Variation in the NS1 sequence has been associated with host range restriction and
virulence (24), and an emerging concept is that NS1 proteins can have distinct
functional properties depending upon the particular viral strain or host species of
isolation. A prime example of this is the interaction of NS1 proteins with host PDZ
domain-containing proteins, which occurs via a speciﬁc 4-amino-acid motif at the C
terminus of NS1 that is predominantly found in avian inﬂuenza A viruses (23). A
functional PDZ domain-binding motif in NS1 can enhance virulence (25), and the short,
linear nature of this well-characterized interaction motif means that certain predictions
regarding the pathobiology of newly emerging inﬂuenza A viruses can be made (26,
27). In contrast, the strain-speciﬁc interaction of NS1 with host CPSF30 can be more
difﬁcult to predict in emerging viruses, as the binding interface is much larger and
nonlinear (28). Experimental studies have shown that the genomes of many human-
adapted inﬂuenza A viruses encode NS1 proteins able to bind and inhibit the normal
function of CPSF30 (29); however, prominent strains that lack this property have been
able to cross the species barrier and infect humans, including the avian H5N1 virus (30),
avian H7N9 virus (31), and swine-origin 2009 pandemic H1N1 virus (32, 33). In addition,
H3N2 inﬂuenza A viruses expressing NS1 variants with destabilized CPSF30 binding
have recently been identiﬁed in human patients (34, 35). In many virus backgrounds,
CPSF30 binding contributes to virulence (31, 35, 36), and although the speciﬁc NS1
amino acid changes that diminish CPSF30 binding differ greatly between strains, the
availability of a crystal structure (28) and multiple NS1-CPSF30 binding studies (29–33,
35, 37, 38) have created large reference data sets to aid in evaluating the pathogenic
potential of newly identiﬁed inﬂuenza A viruses on the basis of their NS1 sequences.
Other than CPSF30, the only known host protein with a structurally deﬁned interface
with NS1 is the p85 regulatory subunit of PI3K (39). Binding of NS1 to p85 activates
the PI3K signaling pathway in infected cells (10), and artiﬁcial mutations in NS1 that
destabilize this interaction attenuate virus replication in vitro and virulence in vivo (10,
40–42). A single naturally occurring amino acid variant in the NS1 proteins of some
highly pathogenic H5N1 avian inﬂuenza virus strains has been associated with altera-
tion of the interaction of NS1 with p85 and an impact on virulence under certain
circumstances (43); however, the existence and prevalence of other functionally similar
variants are unknown. The biological consequences that occur downstream of NS1-
activated PI3K are also not fully understood: triggering of cation conductance in the
infected lung epithelium has been suggested (44), and suppression of virus-induced
apoptosis has been controversial (11, 41, 45), possibly due to the use of different virus
strains and a lack of knowledge surrounding how different NS1 variants from these
strains engage with PI3K. In this study, we sought to comprehensively deﬁne the
p85-binding site in NS1, creating a resource of loss-of-function mutants for further
phenotypic study. We also sought to assess the impact of natural NS1 variants on this
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activity, both to investigate potential host-adaptive strategies and to create a frame-
work for the future rapid characterization of newly emerging inﬂuenza A viruses.
RESULTS
Identiﬁcation of NS1 residues that contribute to p85 binding. Analysis of the
previously published crystal structure of the NS1 effector domain in complex with its
primary binding site on p85 revealed that 20 NS1 residues directly contact p85 (39)
(Fig. 1A). Of these, 3 residues (Y89, E142, and P164) have been previously implicated in
p85 binding (10, 41, 46), although E142 and P164 have only ever been tested for their
contribution in combination with other residues not found at the interface (13, 41, 46).
Notably, F138, the NS1 residue linked to modulation of the p85 interaction in some
H5N1 viruses (43), is not a direct interface residue, suggesting more complex mecha-
nisms by which changes at this position alter virulence. We generated a library of
V5-tagged A/Puerto Rico/8/1934 (H1N1) (PR8) NS1 constructs with individual alanine
substitutions at each of the 20 residues that contact p85 and tested their abilities to
FIG 1 Identiﬁcation of NS1 residues that contribute to p85 binding. (A) Crystal structure of the NS1
effector domain (ED; silver) alone (left) or in complex with a portion of the p85 iSH2 domain (purple)
(right). The 20 NS1 residues that contact p85 are indicated in yellow (see also the NS1 sequence at the
bottom of panel A). Three NS1 residues previously suggested to be important for this interaction are
labeled, while the locations of the four most critical residues identiﬁed in this study (Y89, L95, M98, and
I145) are in blue. The ﬁgure was generated using the PyMOL program (PDB accession number 3L4Q). (B)
(Top) Western blot analysis of anti-V5 immunoprecipitates (IP) from lysates of 293T cells expressing
V5-GST or various V5-PR8 NS1 single amino acid mutants together with FLAG-p85. Proteins of interest
were detected using speciﬁc antibodies. Input samples were similarly processed. (Bottom) Band intensity
was quantiﬁed using a Li-Cor Odyssey scanner. The mean numbers of relative units from three
independent experiments are plotted. Error bars represent standard deviations (SDs). Signiﬁcance was
determined by Students t test (*, P  0.00385). WT, wild type.
IAV NS1 and p85 Binding Journal of Virology
November 2017 Volume 91 Issue 21 e01081-17 jvi.asm.org 3
bind FLAG-tagged human p85 in coimmunoprecipitation assays following cotrans-
fection in 293T cells. As previously described (10), wild-type V5-tagged NS1 efﬁciently
precipitated p85, unlike either the NS1 Y89F mutant or a glutathione S-transferase
(GST) control (Fig. 1B). Of the 20 PR8 NS1 single alanine mutants tested, we observed
that 10 exhibited a loss-of-function phenotype with respect to p85 binding (arbitrarily
deﬁned as a 2-fold reduction in the level of p85 binding compared to that of the
wild type): Y89A, L95A, M98A, S99A, D101A, N133A, I145A, L146A, R148A, and P162A
(Fig. 1B). These loss-of-function mutants had a spectrum of p85 binding: compared to
the wild type, the S99A, D101A, L146A, and R148A mutants showed 2- to 3-fold
reductions in binding, while the L95A, N133A, and P162A mutants showed 3- to 10-fold
reductions. The I145A mutant exhibited a 10-fold reduction in binding, while the
Y89A and M98A mutations had the greatest impact (100-fold and 30-fold reduc-
tions, respectively) (Fig. 1B). The M98A mutant had a p85-binding capacity similar to
that of the well-characterized NS1 Y89F mutant, but the NS1 Y89A mutation abrogated
the p85-binding capacity to an even greater extent (Fig. 1B). Strikingly, of the 3
previously reported contact residues, only Y89 was found to be important for p85
binding: single alanine substitutions at position 142 or 164 had a minimal impact in our
experiments and did not reach the arbitrary 2-fold threshold. These data rationally map
10 PR8 NS1 residues that contribute to p85 binding, and 9 of these are newly
described. Notably, the most important contact residues (Y89, L95, M98, and I145)
cluster together in the three-dimensional structure of NS1, forming a hydrophobic
groove into which the inter-SH2 (iSH2) domain of p85 is inserted (Fig. 1A).
Impact of naturally occurring NS1 variants on p85 binding. The critical con-
tributions of Y89, L95, and M98 (but, interestingly, not the contribution of I145) to p85
binding were conﬁrmed for the 2009 pandemic H1N1 virus NS1 protein (Fig. 2),
suggesting both common and unique features of different NS1 proteins with respect to
this phenotype. Using 24,000 publicly available sequences deposited to the NIAID
Inﬂuenza Research Database (IRD) (47), we therefore further investigated the naturally
occurring variation in NS1 proteins from diverse inﬂuenza A viruses, with a focus on the
20 amino acid residues that make up the p85-binding site. To minimize sampling bias,
we excluded the large number of 2009 pandemic H1N1-derived virus sequences and
considered these viruses separately. As graphically summarized in Fig. 3A, some of the
NS1 residues at this interface are extremely well conserved, including S99, N133, E142,
R148, E159, and P162, as well as the critical Y89 residue. In contrast, we observed
variations at the three other most important p85 contact residues in NS1: 95, 98, and
145. Variants at these positions (e.g., 95L/I/V, 98M/L/I, and 145I/V) largely maintained
hydrophobicity, although notably, 6% of NS1 proteins had 145T, potentially disrupting
the nature of the p85-binding site. Several other sites exhibited variations that
resulted in considerable physicochemical differences, such as 87S/P, 101D/E/N, 118R/K,
135S/N, 143T/N/A, 146S/L, 161S/Y/L, and 164P/L/S. We generated V5-tagged PR8 NS1
constructs with each individual variant observed at the 20 p85 contact residues,
focusing on those variants with a high prevalence (1%), apparent host species
speciﬁcity, or distinct side chain properties. The abilities of these mutants to bind
FIG 2 Assessment of 2009 pandemic H1N1 NS1 residues that contribute to p85 binding. The results of
a Western blot analysis of anti-V5 immunoprecipitates from lysates of 293T cells expressing V5-GST or
various V5-Cal09 NS1 single amino acid mutants together with FLAG-p85 are shown. Proteins of interest
were detected using speciﬁc antibodies. Input samples were similarly processed. Data are representative
of those from three independent experiments.
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FLAG-tagged human p85 in coimmunoprecipitation assays following cotransfection
into 293T cells were then assessed. No single naturally occurring amino acid variant
tested completely abrogated the binding of NS1 to p85 (Fig. 3B). However, 5 NS1
variants appeared to destabilize (by 2- to 5-fold) the p85 interaction: 135N, 145T,
161L/Y, and 164S (Fig. 3B). Interestingly, a single amino acid variant (95I) consistently
resulted in enhanced p85 binding (2-fold) (Fig. 3B). These data largely complement
and conﬁrm our alanine scan-derived observations that a hydrophobic patch consisting
of residues 89, 95, 98, and 145 constitutes a critical core of the p85-binding site. This
patch is highly conserved, maintaining hydrophobic properties, and natural and un-
natural variants that negate hydrophobicity serve to disrupt p85 binding. Further-
more, our variant analysis revealed an important role for residues 135, 161, and 164 that
was not apparent from the alanine scan data alone.
NS1 p85-binding variants have arisen in human IAVs and have functional
consequences. We focused on variants at positions 95, 135, and 145 that promoted or
destabilized p85 binding, as they were commonly found in either previously or
FIG 3 Impact of naturally occurring NS1 variants on p85 binding. (A) Crystal structure of the NS1
effector domain (silver) highlighting naturally occurring variants among the 20 p85 contact residues
(PDB accession number 3L4Q). Each residue is labeled, and the pie charts indicate the prevalence of
various amino acids at each position among 24,000 IAV NS1 sequences obtained from the NIAID
Inﬂuenza Research Database. (B) (Top) Western blot analysis of anti-V5 immunoprecipitates from lysates
of 293T cells expressing V5-GST or various V5-NS1 single amino acid mutants together with FLAG-p85.
Proteins of interest were detected using speciﬁc antibodies. Input samples were similarly processed.
Band intensity was quantiﬁed using a Li-Cor Odyssey scanner. (Bottom) The mean numbers of relative
units from three independent experiments are plotted. Error bars represent standard deviations (SDs).
Statistical signiﬁcance was determined by the Student t test (*, P  0.004545).
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currently circulating human IAVs. Further analysis of the prevalence of these variants
revealed that 95I, which can enhance p85 binding, rapidly arose in NS1 proteins
derived from circulating human H1N1 IAVs in the 1940s (Fig. 4A and B) and was present
in the majority of human H1N1 viruses for several decades until the 2000s, after which
it was gradually replaced by 95V, which is a weaker p85-binding residue than 95I (Fig.
4B). As a consequence of 95I appearing in H1N1 viruses in the 1940s, this variant is also
found in the descendant NS1 proteins of essentially all human H3N2 IAVs, where it has
been maintained (Fig. 4C). Interestingly, in parallel with the disappearance of 95I, 145T
(a residue that weakens p85 binding) emerged in the NS1 proteins of seasonal human
H1N1 viruses, while 135N, another residue in NS1 that weakens p85 binding, has
become dominant in human H3N2 viruses since 2010. To date, 2009 pandemic-derived
seasonal H1N1 viruses have maintained their 1918-like classical swine H1N1 lineage
NS1 sequence at these sites (Fig. 4D). We tested the impact of these residues that
weaken p85 binding, 145T and 135N, on the ability of the NS1 95I construct to interact
with p85, thus mimicking the natural evolution of the p85-binding site in NS1 in
human IAVs. We observed that both of these variants independently had a negative
effect on NS1 binding to p85 in the context of 95I, indicating that the residues that
weaken p85 binding are dominant (Fig. 5A).
From our data, we would predict that NS1 proteins from H1N1 IAVs isolated in the
late 2000s would have a weaker p85-binding capacity than NS1 proteins from early
H1N1 viruses (i.e., PR8, the reference strain used in this study) because of the presence
of the 95V and 145T variant residues. In contrast, we would expect that NS1 proteins
from H3N2 viruses isolated at about the same time would have a much higher
p85-binding capacity due to the presence of 95I, but NS1 proteins from later H3N2
viruses would have diminished binding due to the appearance of 135N. We tested this
by performing p85 coimmunoprecipitation experiments with V5-tagged NS1 proteins
derived from human strains A/Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2),
and A/Boston/DOA2-172/2013 (H3N2) (Fig. 5B). In agreement with our predictions, the
pattern of binding of these NS1 proteins to p85 recapitulated the effects seen with
FIG 4 NS1 p85-binding variants have arisen in human IAVs. (A) Sequence alignment of NS1 proteins
from early human H1N1 IAVs highlighting the emergence of 95I. BM18, A/Brevig Mission/1/1918 (H1N1);
Melbourne/35, A/Melbourne/1935 (H1N1); Henry/36, A/Henry/1936 (H1N1); Hickox/40, A/Hickox/1940
(H1N1); Bel/42, A/Bel/1942 (H1N1); Weiss/43, A/Weiss/1943 (H1N1). (B) Graph indicating the evolution of
residues 95 and 145 in H1N1 IAVs (excluding the 2009 pandemic virus). H1/Brisbane/07, A/Brisbane/59/
2007 (H1N1). The percentage of isolates harboring a particular residue within the indicated period is
plotted. n, the number of isolates analyzed per time point; *, results for the years 2006 to 2008 (data are
for 708 isolates). Selected strains are highlighted. (C and D) Same as panel B, but for H3N2 (C) and 2009
pandemic H1N1 (D) viruses. H3/Boston/13, A/Boston/DOA2-172/2013 (H3N2); H3/Brisbane/07, A/Bris-
bane/10/2007 (H3N2). **, results for the years 2014 and later (data are for 2,200 isolates).
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single and double variant mutations in our reference NS1 construct. These data indicate
that NS1 variation at allosteric sites that may also have accumulated over time has no
compensatory impact on the p85-binding capacity, and suggest that IAV NS1 proteins
that have evolved in humans over the last century exhibit temporal variation in their
p85-binding capacity that is predictable on the basis of our new functional annotation
of the p85-binding site.
NS1 p85-binding variants in human IAVs do not switch p85 isoform speciﬁc-
ity.We considered that the p85-binding variation in NS1 could be a result of adaptive
mutations allowing NS1 to bind another human host protein. p85 is an alternative
regulatory subunit of class IA PI3Ks, and its iSH2 domain is highly homologous to that
of p85, although strikingly, this subunit is not targeted by NS1 (10). Indeed, it has
previously been shown that only a single amino acid change in this domain of p85
(M582V) can allow the binding of NS1 (Fig. 6A) (46). Notably, NS1 residue 145 lies in
close proximity to this binding determinant (Fig. 6B); therefore, we tested whether any
of the human IAV NS1 variants had gained the capacity to bind p85. In coimmuno-
precipitation assays, wild-type V5-tagged NS1, but not a GST control, was able to
FIG 5 Human IAV NS1 p85-binding variants have functional consequences. (A) Western blot analysis of
anti-V5 immunoprecipitates from lysates of 293T cells expressing V5-GST or various V5-NS1 mutants
together with FLAG-p85. (B) Same as panel A, but including V5-NS1 proteins derived from the indicated
virus strains. The sequences at key residues are indicated at the top. For both panel A and panel B,
proteins of interest were detected using speciﬁc antibodies. Input samples were similarly processed.
Band intensity was quantiﬁed using a Li-Cor Odyssey scanner. The mean numbers of relative units from
three independent experiments are plotted. Error bars represent standard deviations (SDs). Signiﬁcance
was determined by the Student t test (*, P  0.05).
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precipitate FLAG-tagged p85, but neither V5-tagged construct could precipitate
FLAG-tagged p85 (Fig. 6C). Similarly, isogenic V5-tagged NS1 proteins with variations
at position 95, 135, or 145, as well as V5-tagged NS1 proteins from human strains
A/Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2), and A/Boston/DOA2-172/2013
(H3N2), were also unable to bind p85 (Fig. 6C and D). These data indicate that
mutations that have accumulated in the p85-binding site of NS1 proteins from human
IAVs do not impact the selectivity of NS1 for p85 over p85.
Impact of NS1 p85-binding variants on IAV replication and competitive ﬁtness.
The accumulation and maintenance of speciﬁc variants at the p85-binding site in the
NS1 proteins of circulating human IAVs may suggest that those variants provided a
selective advantage to IAVs in humans. In order to test this hypothesis, we generated
isogenic PR8-based viruses expressing NS1 proteins with the L95I amino acid change
(PR8/NS1-L95I) or double L95V/I145T amino acid changes (PR8/NS1-L95V/I145T) to
represent the p85-binding capacity of H1N1 viruses isolated in about the 1940s or the
late 2000s, respectively. In agreement with their impact on p85 binding, we found
that these variants had predictable effects on activation of PI3K signaling during
infection, as determined by Western blotting for the activated form of the downstream
PI3K effector kinase, Akt: kinetic studies revealed a slightly enhanced level of phos-
phorylated Akt (pAkt) at later time points during infection with PR8/NS1-L95I compared
to that during infection with the wild type, while PR8/NS1-L95V/I145T induced lower
levels of pAkt at early time points (Fig. 7A). However, it was clear that both mutant
viruses ultimately induced pAkt levels to a much greater extent than the PR8/NS1-Y89F
control, whose NS1 protein lacks a detectable p85-binding capacity. PR8/NS1-Y89F is
attenuated for virus replication compared to wild-type virus in human lung epithelial
A549 cells (Fig. 7B) (40). We therefore also assessed the replication kinetics of the
PR8/NS1-L95I and PR8/NS1-L95V/I145T viruses to see if this correlated with their
p85-binding ability and level of pAkt induction. Perhaps reﬂecting the subtlety of
these variants on the NS1-p85 interaction, we did not ﬁnd a statistically signiﬁcant
FIG 6 Human IAV NS1 p85-binding variants do not switch p85 isoform speciﬁcity. (A) Structures of the
iSH2 domains of p85 (green; PDB accession number 2V1Y) and p85 (purple; PDB accession number
3L4Q). Residues of the p85 iSH2 domain that differ from the p85 sequence are highlighted. Human
M582 (p85) and V579 (p85) are labeled as potential contact residues with NS1. (B) Close-up of the
interface between NS1 and p85 (PDB accession number 3L4Q). Critical NS1 residues with functional
variants are labeled, and the p85 iSH2 domain is superpositioned to indicate the relative positioning of
p85M582. (C) Western blot analysis of anti-V5 immunoprecipitates from lysates of 293T cells expressing
V5-GST or various V5-NS1 mutants together with either FLAG-p85 or FLAG-p85. (D) Same as panel C,
but including V5-NS1 constructs derived from the indicated strains. For both panel C and panel D,
proteins of interest were detected using speciﬁc antibodies. Input samples were similarly processed. Data
are representative of those from at least two independent experiments.
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enhancement of PR8/NS1-L95I virus replication or a defect in PR8/NS1-L95V/I145T virus
replication compared to wild-type virus replication when measuring viral titers in the
supernatants of infected A549 cells by a plaque assay (Fig. 7C). Nevertheless, we
consistently observed that the PR8/NS1-L95I virus appeared to replicate slightly better
than the wild type, although the titers were only 2-fold higher. To investigate this
further, we therefore established a more sensitive competition-based assay in A549
cells where we could serially passage deﬁned mixtures of the wild-type PR8 and
PR8/NS1-L95I viruses to determine whether one could outcompete the other. Strikingly,
at an input mixture ratio of 1:1 and in 6/6 replicates over 2 independent experiments,
the PR8/NS1-L95I virus dominated over the wild-type virus within 1 to 2 passages (Fig.
8A). When a more stringent mixture ratio of 5:1 (wild type/mutant) was used, the
PR8/NS1-L95I virus also showed a trend to outcompete the wild-type virus, although,
as expected, this took more passages (Fig. 8B). Similarly, the PR8/NS1-L95I virus was
able to outcompete the PR8/NS1-L95V/I145T virus (Fig. 8C and D). Parallel control
passaging of each virus alone did not result in any spontaneous mutations in NS1.
These data indicate that the naturally occurring 95I variant in the p85-binding site of
NS1 imposes a subtle growth advantage on a recombinant virus derived from a virus
isolated in the 1930s. This experimental observation is consistent with the appearance
of NS1 95I in human IAV strains in the 1940s, which effectively became ﬁxed for the
duration of the 20th century, and may suggest that this change was a contributor to
effective adaptation to the human host.
Covariation of NS1 p85-binding phenotypes with functional changes in other
IAV proteins. While the observed reduced ﬁtness of the PR8/NS1-L95V/I145T virus
complements the ﬁndings from studies introducing artiﬁcial mutations into NS1 to
destabilize its interaction with p85 (10, 40), it is surprising that a virus with such a
phenotype of weakened binding presumably exhibited enhanced ﬁtness in the human
population to become dominant. We therefore speculate that other viral factors which
were not effectively modeled in our tissue culture experiments using a noncontempo-
raneous recombinant virus may have contributed to the emergence of this phenotype
in vivo. As a ﬁrst step to uncover such factors, we performed evolutionary analyses on
all human H1N1 and H3N2 viral proteins from viruses isolated over the last century to
identify potential residues that covaried with H1N1 and H3N2 NS1 145T and 135N,
respectively (summarized in Table 1). As expected, multiple amino acid variants oc-
FIG 7 Impact of NS1 p85-binding variants on IAV-induced Akt phosphorylation and replication in vitro.
(A) Western blot analysis of total lysates of HAP1 cells infected with the indicated rPR8-based NS1
wild-type (WT) or mutant virus at an MOI of 5 PFU/cell for 2, 4, or 6 h. Proteins of interest were detected
using speciﬁc antibodies. Data are representative of those from at least three independent experiments.
VT, L95V/I145T. (B and C) Growth curve analysis of the indicated rPR8-based NS1 wild-type or mutant
virus in A549 cells (MOI  0.01 PFU/cell). Supernatants from the indicated time points were titrated in
MDCK cells. Data points show mean values from three independent experiments  SDs.
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curred at these times during evolution, and functionally equivalent changes between
H1N1 and H3N2 viruses (perhaps resulting from disparate amino acid changes) are
difﬁcult to determine. Nevertheless, we observed that in two viral proteins, NA and PB2,
the same amino acid positions appeared to covary with the NS1 p85-binding phe-
notype, even though such a phenotype arose independently in H1N1 and H3N2 viruses
at least 15 years apart and arose with different causative sequence changes. In NA, S367
was replaced by either phenylalanine (H1N1) or asparagine (H3N2). Changes at this
position have been functionally implicated in altering the second sialic acid-binding site
in NA and are associated with avian-to-human host adaptation and, possibly, tissue
tropism (48, 49). In PB2, T613 was replaced by either isoleucine (H1N1) or alanine
(H3N2), and variants at this position have also been identiﬁed bioinformatically to be
potential host signatures (50, 51). These preliminary analyses therefore identify at least
two functional changes in NA and PB2 that covary with the NS1 p85-binding pheno-
type during virus evolution in humans. This may provide a starting point to investigate
the natural emergence of NS1 p85-binding variants with apparently compromised
ﬁtness proﬁles in vitro.
DISCUSSION
Although the binding of the IAV NS1 protein to host p85 and the subsequent
activation of PI3K signaling are well documented (10–13, 39, 46), the downstream
impact of this virus-host interaction has often been controversial (11, 41, 45), possibly
because investigators use different virus strains, cell models, chemical inhibitors, or
arbitrary NS1 mutants. In the study described here, we used a rational structure-guided
approach to identify IAV NS1 mutants exhibiting a loss-of-function phenotype with
respect to host p85 binding. Our results expand on the knowledge that Y89 is an
essential NS1 determinant of this interaction by identifying 9 other NS1 residues that
FIG 8 Impact of NS1 p85-binding variants on IAV ﬁtness in vitro. A549 cells were initially infected with
the indicated mixture of rPR8-based NS1 wild-type (WT) or mutant virus at an MOI of 0.01 PFU/cell. For
each passage, supernatants were harvested after 48 h, titrated, and used for subsequent passages at the
same MOI. The graphs depict the relative prevalence of the indicated segment at each passage (P), as
determined by Sanger sequencing and analysis of the relevant codon. Each point represents data from
a single infected well of a single experiment (3 wells in each of 2 independent experiments). Rel. seq.,
relative sequence; VT, L95V/I145T.
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play additional roles, with the most important ones being residues 95, 98, 133, 145, and
162. These data provide a new panel of functionally deﬁned mutants that can be used
in future studies to elucidate the biological consequences of NS1 activation of PI3K
signaling during IAV infection. This resource will allow a comparative phenotypic
assessment of different viral mutants with a common functional defect, an experimen-
tal strategy that will limit the overinterpretation of data due to reliance on a mutant
with a single arbitrary NS1 mutation. Given the multifunctionality of NS1 (1, 3), it is very
likely that particular loss-of-function mutations can have more than one consequence.
For example, it is known that some mutations used to disrupt the NS1-CPSF30
interaction also impact the ability of the NS1 effector domain to form homotypic
interactions (52–54) and can have CPSF30-independent consequences (55). Therefore,
biological studies performed with multiple independent NS1 mutants with common
host protein binding properties are highly desirable to dissect NS1 functions. Our data
can also be used to reinterpret the results of existing observational studies. For
example, experiments aimed at adapting a human IAV isolate to mice identiﬁed a single
NS1 variant at position 98 that increased virulence (98S) (38, 56). The molecular
mechanisms underlying this phenotype might now also be considered in the context
of the resource presented here that NS1 98S may exhibit altered p85-binding prop-
erties.
We also used our rational structure-guided approach to assess the impact of
naturally occurring amino acid variants in NS1 at its interface with p85. This revealed
that IAV NS1 proteins can exhibit a spectrum of p85 binding which is largely
determined by variations at positions 95, 135, 145, 161, and 164. Strikingly, we observed
that variants at positions 95, 135, and 145 arose and were maintained in human IAVs
for periods of time over the last 100 years. This led to predictable alterations in the
p85-binding capacity: human IAV NS1 proteins with 95I (prevalent from the 1940s
onwards) exhibited enhanced binding toward p85, while independent variants at
positions 135 and 145 destabilized p85 binding and became more prevalent in both
H1N1 and H3N2 IAV NS1 proteins from the end of the 20th century onwards. In our
experimental model system utilizing isogenic PR8-based viruses (isolated in 1934), we
were able to demonstrate a competitive growth advantage for an IAV expressing NS1
with the 95I (p85-binding-enhancing) variant, which would appear to be in line with
its rapid selection in humans. This correlation suggests a beneﬁt conferred to these
viruses by enhanced p85 binding. Nevertheless, variants that destabilize p85 binding
(135N or 145T) have recently emerged and been selected for in human IAVs, and our
sensitive competition assay would suggest that, at least in the PR8-based background,
such destabilizing variants are deleterious to virus propagation compared with the
propagation ability of the preceding virus, which exhibited enhanced p85 binding
(95I). How viruses expressing such NS1 variants therefore established themselves in
the human population is unknown, and we can only speculate that compensatory or
synergistic functional changes in other viral properties (highlighted in our evolutionary
analyses as a potential interplay with NA or PB2 proteins) could have played a role.
It is currently unclear whether the evolution of the NS1 p85-binding site in humans
is directly related to a requirement to alter a PI3K-related function. Indeed, it also
remains to be determined whether the subtle differences in ﬁtness phenotypes that we
observed are dependent upon p85. Our assays revealed that even IAV NS1 proteins
with partially weakened p85 binding were able to stimulate PI3K activity to a
substantial extent at later times of infection. Thus, it may be that the natural magnitude
of IAV NS1-induced PI3K activation can vary if the net biological consequences (i.e.,
downstream signaling) remain unaffected. In this regard, it is not inconceivable that the
p85-binding capacity is maintained within a ﬂexible range but is in conﬂict with
variant selection that promotes NS1 functional adaptation to other host factors, for
example, TRIM25 or Riplet, to which NS1 binding is species speciﬁc and involves NS1
residues close to the p85-binding site (4). Further studies are required to investigate
such possibilities, as well as the potential interdependence of p85-binding evolution
with other viral factors.
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In summary, the data resource presented here can be used for the rapid, sequence-
based prediction of the p85-binding capacity of any given IAV NS1 protein. Although
potential correlations with the host range, replicative capacity, or virulence must still be
determined using additional sensitive experimental models, this information will be
invaluable for fully characterizing the biology of both newly emerging IAVs in the future
and IAVs of interest as they evolve in particular hosts.
MATERIALS AND METHODS
Cells. MDCK, 293T, and A549 cells were cultured in Dulbecco’s modiﬁed Eagle medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 g/ml streptomycin
(Gibco Life Technologies). HAP1 cells (Horizon Discovery, Vienna, Austria) were cultured in Iscove’s
modiﬁed Dulbecco’s medium (IMDM) supplemented with the same additives mentioned above as well
as 200 M GlutaMAX (Gibco Life Technologies). All cells were maintained at 37°C with 5% CO2.
Construction of plasmids. The NS1 cDNA sequences from A/Puerto Rico/8/1934 (PR8; H1N1), A/Cali-
fornia/04/09 (Cal09; 2009 pandemic H1N1), A/Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2), and
A/Boston/DOA2-172/2013 (H3N2) were PCR ampliﬁed from existing plasmids (or reverse transcription-PCR
[RT-PCR] products) and were ligated in frame with an N-terminal V5 tag in a modiﬁed pLVX-IRES-ZsGreen1
plasmid (Clontech, CA). A pLVX-IRES-ZsGreen1 plasmid carrying GST with a C-terminal V5 tag was generated
in a similar manner. A two-step overlap PCR was used to introduce site-directed mutations into the cDNAs as
required. All NS1 cDNAs also contained silent mutations to prevent expression of the nuclear export protein
(NEP) and were modiﬁed as required to prevent NS1 binding to CPSF30 (103S/106I). The pPolI-based
construct expressing the wild-type PR8 NS segment was kindly provided by Adolfo García-Sastre (Icahn
School of Medicine at Mount Sinai, New York, NY, USA) and was used as a template for site-directed
mutagenesis reactions using a QuikChange II site-directed mutagenesis kit (Stratagene, TX). The identity of all
constructs used was conﬁrmed by sequencing.
Coimmunoprecipitation analysis. Using the FuGENE 6 reagent (Promega), 293T cells seeded in
25-cm2 ﬂasks were transfected with 2 g of the pLVX-IRES-ZsGreen1 plasmid (Clontech, CA) carrying
V5-tagged NS1 proteins or GST (as appropriate) and 1 g of the p3FLAG-CMV7.1 plasmid (Sigma-
Aldrich, MO) expressing FLAG-tagged human p85 or human p85 (provided by Hannah L. Turkington,
University of Zurich, Zurich, Switzerland). At 48 h posttransfection, cells were lysed in 1 ml of passive lysis
buffer (50 mM Tris-HCl [pH 7.8], 500 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40 substitute) supplemented with
a cOmplete Mini protease inhibitor tablet as indicated by the manufacturer (Roche). Following sonication and
clariﬁcation by centrifugation, soluble fractions were incubated for 2 h at 4°C with anti-V5 antibody (Bio-Rad).
Lysate-antibodymixes were then incubated overnight at 4°C with protein G-Sepharose beads (Sigma-Aldrich).
Following extensive washing with passive lysis buffer, a urea-based disruption buffer (6 M urea, 2 M
-mercaptoethanol, 4% SDS) was used to dissociate precipitated proteins from the beads. Samples were
stored at 20°C until analysis by SDS-PAGE and Western blotting.
Construction and functional analysis of recombinant viruses. Recombinant A/Puerto Rico/8/1934
(rPR8) viruses were rescued and titrated essentially as described previously (57). Brieﬂy, using the FuGENE
6 reagent (Promega), 6  105 293T cells were seeded in 6-well plates and cotransfected 24 h later with
7 ambisense pDZ-based expression plasmids expressing the PR8 segments nucleoprotein (NP), PA, PB1,
PB2, matrix (M), hemagglutinin (HA), and neuraminidase (NA) and a pPolI-based plasmid carrying the
PR8 NS segment. At 24 h posttransfection, the cells were washed once in sterile phosphate-buffered
saline (PBS) and 3  105 MDCK cells in DMEM supplemented with 1 g/ml tosylsulfonyl phenylalanyl
chloromethyl ketone (TPCK)-treated trypsin (Sigma-Aldrich, MO) were added. Forty-eight hours later, the
supernatants were harvested, the viruses were plaque puriﬁed, and virus stocks were grown and titrated
using standard methods in MDCK cells. RNA was extracted from stock aliquots using a ReliaPrep RNA
tissue miniprep system (Promega), and the NS genomic segments of each virus were fully sequenced
after segment-speciﬁc RT-PCR to ensure the absence of undesired mutations.
To determine virus replication kinetics, 5 105 A549 cells were seeded in 12-well plates and infected
24 h later with the indicated virus diluted in PBS supplemented with 100 units/ml penicillin and 100
g/ml streptomycin (Gibco Life Technologies), 0.45% bovine serum albumin (Sigma-Aldrich), and 1 mM
Ca2	-Mg2	 at a multiplicity of infection (MOI) of 0.01 PFU/cell. Following 1 h of adsorption, cells were
washed three times in FBS-free DMEM and incubated in FBS-free DMEM supplemented with 0.5 g/ml
TPCK-treated trypsin (Sigma-Aldrich, MO). The supernatants were harvested at the times indicated above
and titrated by plaque assay on MDCK cells.
To perform competition assays, 5  105 A549 cells were seeded in 12-well plates and infected 16 to
24 h later with the mixed inocula (ratios of 1:1 or 5:1) indicated above at an MOI of 0.01 PFU/cell.
Following 1 h of adsorption, the cells were treated as described above. The supernatants were collected
at 48 h postinfection (p.i.) (passage 1), titrated by plaque assay on MDCK cells, and used for repeated
infection of A549 cells to generate virus for passage 2. This procedure was repeated until the passage
number indicated above. RNA was extracted from the supernatants of each passage and the input
inoculum using a ReliaPrep RNA tissue miniprep system (Promega), and the NS genomic segments were
fully sequenced after segment-speciﬁc RT-PCR. Quantiﬁcation of NS segment prevalence was performed
by determining the relative peak height of the unique bases of mutant or wild-type codons using BioEdit
sequence alignment editor software following commercial Sanger sequencing (GATC Biotech, Germany).
To determine the levels of virus-induced Akt phosphorylation, 5  105 HAP1 cells were seeded in
poly-L-lysine (Sigma-Aldrich)-precoated 12-well plates. Following attachment, the cells were washed
three times prior to incubation overnight in serum-free IMDM. The cells were infected with the virus
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indicated above diluted in PBS supplemented with 100 units/ml penicillin and 100 g/ml streptomycin
(Gibco Life Technologies), 0.45% bovine serum albumin (Sigma-Aldrich), and 1 mM Ca2	-Mg2	 for 1 h at
an MOI of 5 PFU/cell. Following three washes with PBS, infected cells were maintained in FBS-free IMDM,
and total protein lysates were harvested at the times postinfection indicated above in a urea-based
disruption buffer (6 M urea, 2 M -mercaptoethanol, 4% SDS). Samples were stored at 20°C until
analysis by SDS-PAGE and Western blotting.
SDS-PAGE and quantitative Western blotting. Samples were sonicated to shear the nucleic acids
and then boiled for 5 min. Polypeptides were resolved by SDS-PAGE on NuPAGE 4 to 12% bis-Tris protein
gels (Thermo Fisher), followed by transfer to nitrocellulose membranes. Proteins were detected by
Western blotting using the following primary antibodies: mouse anti-V5 (catalog number MCA1360;
Bio-Rad), mouse anti-FLAG (catalog number F1804; Sigma-Aldrich), rabbit anti-actin (catalog number
A2103; Sigma-Aldrich), mouse anti-Akt (catalog number 2920; Cell Signaling Technology), and rabbit
anti-pAkt (phosphorylated at S473; catalog number 4060; Cell Signaling Technology). Secondary anti-
bodies were ﬂuorochrome-conjugated anti-mouse immunoglobulin (catalog number 35519; Thermo
Fisher Scientiﬁc) and anti-rabbit immunoglobulin (catalog number SA5-10036; Thermo Fisher Scientiﬁc,).
A Li-Cor Odyssey scanner was used for detection.
Structural and bioinformatic analyses. Structural representations were visualized using the appro-
priate Protein Data Bank (PDB) ﬁle and the PyMOL program (58). All NS1 protein sequence data were
obtained and analyzed using tools from the NIAID Inﬂuenza Research Database (IRD) (47) (http://www
.ﬂudb.org).
Evolutionary analyses. IAV sequences (almost complete open reading frames, preferably from
isolates for which all eight segments have been sequenced) were downloaded from the NCBI Inﬂuenza
Virus Database (59) and aligned using the MEGA (version 5) program (60). A preliminary phylogenetic
tree of each segment for which 500 sequences were available was calculated, and most of the
redundant sequences were removed to yield alignments containing between 100 and 200 representative
sequences. The alignments were used for tree inference with the MEGA (version 5) program (neighbor-
joining method; substitution model, uncorrected p distance; units, number of amino acid differences per
site). Statistical support was estimated with a bootstrap test (1,000 replicates). Persisting amino acid
exchanges correlating with the L95I, I145T, and S135N substitutions of NS1 were identiﬁed in the
alignments.
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